Overview upon miR-21 in lung cancer: focus on NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Lung cancer has a high mortality rate, necessitating novel biomarkers for early detection and improved therapeutic strategies.
• MicroRNAs (miRNAs) are crucial regulators in cancer, offering new avenues for managing lung cancer and other diseases.
• MiR-21 is a well-studied oncogenic miRNA frequently overexpressed in non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To review the mechanisms of action of miR-21 in cancer, focusing on NSCLC.
• To explore the role of miR-21 in NSCLC signaling, prognosis, and therapeutic potential.
• To highlight the association between elevated miR-21 expression and worse outcomes in NSCLC patients.

Main Methods:

• Literature review of studies on miR-21 in cancer, particularly NSCLC.
• Analysis of data from resources like The Cancer Genome Atlas (TCGA) regarding miR-21 expression.
• Examination of miR-21's impact on cancer-related pathways and therapeutic strategies.

Main Results:

• Upregulated miR-21 expression is consistently observed in NSCLC patients, linked to poorer prognosis.
• MiR-21 promotes cancer progression in NSCLC by targeting genes involved in cell growth, angiogenesis, invasion, metastasis, and resistance to therapy.
• Therapeutic strategies targeting miR-21, such as antisense sequences, have demonstrated potential in inhibiting NSCLC.

Conclusions:

• MiR-21 is a significant oncogene in NSCLC, impacting multiple oncogenic pathways and patient outcomes.
• Understanding miR-21's multifaceted role is crucial for developing effective diagnostic and therapeutic approaches for NSCLC.
• Targeting miR-21 represents a promising therapeutic avenue for improving NSCLC management.